Trump Administration to Announce All States Joining Medicaid Drug Pricing Model
The initiative aims to lower prescription drug costs by aligning prices with those paid in other developed nations.
President Donald Trump is scheduled to announce Friday that all 50 states will participate in a program designed to implement most favored nation pricing for certain Medicaid drugs. The initiative, dubbed the Medicaid “GENEROUS” model, seeks to reduce the net price of selected medications to levels comparable to those paid in other developed countries.
The Trump administration estimates that this plan will lead to billions of dollars in savings for Medicaid on prescription drug expenditures. However, experts note that the precise savings remain unclear due to the limited public disclosure of the specific terms of these agreements.
This announcement comes as cost-of-living concerns are a prominent issue for voters leading up to the midterm elections. In an effort to address affordability, the administration has negotiated with pharmaceutical companies to cap the prices of some drugs in the U.S. at levels not significantly higher than those in other affluent nations. This approach follows an executive order signed last year establishing a “Most Favored Nations” policy, committing the U.S. to pay the lowest price for medications globally.
Last May, the White House projected that these deals could save $529 billion over the next decade. While patients enrolled in Medicaid, a program for low-income individuals, already pay minimal co-payments for prescriptions, the reduced drug prices could offer financial relief to state budgets that contribute to the program.
The lack of transparency regarding the specifics of the deals with pharmaceutical companies makes it challenging for independent verification of the projected savings. Kathy Hempstead, a senior policy advisor at the Robert Wood Johnson Foundation, has indicated that there is considerable pressure on the administration to provide more detailed data to substantiate its cost-saving claims. She stated that the absence of this information impedes potential legislative action, as it is unclear what Congress would be able to codify without knowing the precise contents of the agreements.
Concerns have also been raised about the long-term sustainability of these price reductions, particularly whether they will persist beyond the current administration's term. JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, acknowledged the announcement as "meaningful progress" but emphasized that it remains incomplete, as millions of Americans not covered by government healthcare programs still seek lower drug prices.